{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:21:19Z","timestamp":1772108479403,"version":"3.50.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide. Particularly, cases of bone metastasis have poorer prognoses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>A 62-year-old woman with suspected advanced HCC accompanied by bone metastasis with severe back pain and sciatica showed disease remission after cyproheptadine monotherapy. Initially, her serum alpha fetal protein (AFP) level was high, reaching up to 17697.62 ng\/ml. A dose of 4 mg cyproheptadine, 3 times a day for 17 months was prescribed as the only treatment. Within 3 months, the serum AFP level gradually normalized down to 4.3 ng\/ml. Both liver biopsy and bone biopsies were subsequently performed after 2 weeks of cyproheptadine. The results showed no malignancy. During the 34 months of follow-ups, the serum AFP remained normal in the range of 1.05 to 2.86 ng\/ml. The patient has survived for 5 years without back pain and sciatica thus far.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This is the first report to investigate a successful clinical approach in cyproheptadine monotherapy for an advanced HCC patient with bone metastasis. We recommend cyproheptadine as a potential anti-HCC agent for the treatment of HCC with bone metastasis, but more related studies such as prospectively clinical trials, and ideally randomized trials are still needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.620212","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T05:26:29Z","timestamp":1634707589000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report"],"prefix":"10.3389","volume":"11","author":[{"given":"Yu-Min","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Hsien","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dara","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu-Kuang","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Sheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chih","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.7024","article-title":"Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma","volume":"16","author":"Harding","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","first-page":"bcr2012007180","DOI":"10.1136\/bcr-2012-007180","article-title":"Unexpected Remission of Hepatocellular Carcinoma (HCC) With Lung Metastasis to the Combination Therapy of Thalidomide and Cyproheptadine: Report of Two Cases and a Preliminary HCC Cell Line Study","volume":"2012","author":"Feng","year":"2012","journal-title":"BMJ Case Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and Safety of Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cld.879","article-title":"Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma","volume":"15","author":"Huppert","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e512\u20139","DOI":"10.1634\/theoncologist.2019-0501","article-title":"Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis","volume":"25","author":"Kim","year":"2020","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12885-015-1137-9","article-title":"Cyproheptadine, an Antihistaminic Drug, Inhibits Proliferation of Hepatocellular Carcinoma Cells by Blocking Cell Cycle Progression Through the Activation of P38 MAP Kinase","volume":"15","author":"Feng","year":"2015","journal-title":"BMC Cancer."},{"key":"B8","first-page":"584","article-title":"Cyproheptadine Use in Hepatocellular Carcinoma","volume":"7","author":"Hsieh","year":"2017","journal-title":"Am J Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-017-9998-6","article-title":"Hepatocellular Carcinoma With Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience","volume":"48","author":"Bhatia","year":"2017","journal-title":"J Gastrointest Cancer."},{"key":"B10","article-title":"Space-Occupying Lesions of the Liver","volume-title":"Imaging in Hepatobiliary and Pancreatic Disease: A Practical Clinical Approach","author":"van Leeuwen","year":"2000"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3390\/cancers12061610","article-title":"The Antihistamine Deptropine Induces Hepatoma Cell Death Through Blocking Autophagosome-Lysosome Fusion","volume":"12","author":"Liang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2015.09.018","article-title":"Cyproheptadine Exhibits Antitumor Activity in Urothelial Carcinoma Cells by Targeting GSK3beta to Suppress Mtor and Beta-Catenin Signaling Pathways","volume":"370","author":"Hsieh","year":"2016","journal-title":"Cancer Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/35077213","article-title":"Proliferation, Cell Cycle and Apoptosis in Cancer","volume":"411","author":"Evan","year":"2001","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22580","article-title":"Molecular Mechanisms of Hepatocellular Carcinoma","volume":"48","author":"Aravalli","year":"2008","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9524075","article-title":"Role of Histamine in Modulating the Immune Response and Inflammation","volume":"2018","author":"Branco","year":"2018","journal-title":"Mediators Inflamm"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nm1780","article-title":"Aggravation of Viral Hepatitis by Platelet-Derived Serotonin","volume":"14","author":"Lang","year":"2008","journal-title":"Nat Med"},{"key":"B17","article-title":"Analysis of the Effects of Cyproheptadine on Bladder Cancer Through Big Data","volume":"10","author":"Chang","year":"2020","journal-title":"Am J Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.620212\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T05:30:31Z","timestamp":1634707831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.620212\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":17,"alternative-id":["10.3389\/fonc.2021.620212"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.620212","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"article-number":"620212"}}